Business Wire

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

12.5.2022 09:00:00 EEST | Business Wire | Press release

Share

Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)

The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.

Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.

The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.

Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”

Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”

###

About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.

About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com

Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Partners With Bolt to Grow ‘Pay in Full’ for Rides and Scooters17.6.2026 11:20:00 EEST | Press release

Klarna, the global digital bank and payments provider, has partnered with Bolt, the European shared mobility platform, to bring Klarna's payment options directly into the Bolt app. Across Sweden, Germany, Finland and Norway, users can now pay for car rides and scooters with Klarna, with car rentals also available in Germany. The integration is built on tokenised payments, allowing users to pay through their stored credentials without re-entering details for each trip. In all four markets, customers can choose to pay in full or pay monthly with Klarna. The rollout is already underway, with full availability across all four markets expected by the end of June 2026. The partnership brings together two of Europe's largest consumer platforms: Bolt serves more than 200 million customers across over 50 countries, while Klarna has over 119 million active users worldwide. For Klarna, it deepens a growing presence in everyday, high-frequency spending, placing the company at the point of payment

Ohmium and Hynfra Sign Master Cooperation Agreement to Advance Large-Scale Green Hydrogen Projects in the Middle East and Africa17.6.2026 11:17:00 EEST | Press release

Ohmium International Inc., a leading manufacturer of high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, and Hynfra P.S.A., a prominent green hydrogen and green ammonia project developer, today announced the signing of a master cooperation agreement to advance green hydrogen projects in Mauritania, Jordan, and Oman. The cooperation agreement covers the projects’ Front-End Engineering and Design (FEED) stage and establishes the framework for ongoing collaboration. Ohmium also will provide technical support and PEM electrolyzer expertise throughout the FEED and development stages for the three hydrogen projects mentioned. These projects are designed to produce green hydrogen for green ammonia applications, advancing energy security and long-term resilience in host countries by building domestically sourced clean energy capacity and reducing dependence on imported fossil fuels, while also supplying RFNBO-compliant green ammonia for export, including to European markets.

ID UNLIMITED Strengthens European Platform With Acquisition of Denmark’s Jet Sport17.6.2026 11:00:00 EEST | Press release

ID UNLIMITED, a European leader in premium equipment personalisation and embellishment services for sports clubs, leagues and global sports brands, has signed an agreement to acquire Jetsport A/S (“Jet Sport”), a provider of personalisation and customisation services headquartered in Viborg, Denmark, specialised in sportswear and workwear. Jet Sport marks the first acquisition under ID UNLIMITED's international expansion strategy since partnering with TowerBrook Capital Partners in April this year. The transaction is expected to close by the end of June 2026, subject to customary conditions. Founded in 1971, Jet Sport is a family-owned business with over five decades of experience in textile embellishment. The company serves sports clubs, sporting goods retailers, workwear suppliers and industrial clients, providing high-quality screen prints, heat transfers and embroideries with approximately 140 employees. Jet Sport has built a reputation for quality, fast turnaround and technical in

Reply Achieves the AWS Business Value Realization Competency17.6.2026 11:00:00 EEST | Press release

Reply [EXM, STAR: REY] announced today that it has achieved the Amazon Web Services (AWS) Business Value Realization Competency. This specialization recognizes Reply as an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617874809/en/ Reply achieves the Amazon Web Services (AWS) Business Value Realization Competency that recognizes an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. Achieving the AWS Business Value Realization Competency differentiates Reply as an AWS Partner that excels at helping customers define, measure, and achieve business outcomes from their cloud and AI investments. It signals to customers that a Partner has the commitment, trained and certified teams, and a proven track record of delivering measurable outcomes, not just technical

LTM Launches BlueVerse™ on Databricks to Accelerate AI Monetization17.6.2026 10:46:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse for Databricks, a new offering that brings together LTM’s AI ecosystem, BlueVerse™, with Databricks, the Data and AI company, to accelerate AI-driven data monetization. BlueVerse for Databricks is designed to help enterprises drive tangible business outcomes from data and AI investments by addressing critical challenges in the secure and efficient management of data and compute resources, while optimizing business processes and providing pre-built industry solutions to unlock greater value from AI initiatives. LTM BlueVerse helps companies reimagine core business processes such as procure-to-pay, order-to-cash, hire-to-retire, and marketing operations as AI-optimized workflows. It also enables organizations to accelerate time-to-value through pre-built, industry-specific solutions for Manufacturing, Banking, Financial Services, Insurance, Media & Entertainment, and Retail &

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye